This chapter gives decision makers and compliance teams a clear, citable map of India’s drug regulatory framework — what laws and rules apply, how approvals work (including imports/exports), how clinical trials are governed, and how price control interacts with market access. For any pharmaceutical company legal advisory India or legal service professional in India advising pharma clients, this framework represents the essential foundation of regulatory practice in India.

Core Law & Institutions

India’s medicines and cosmetics are governed primarily by the Drugs & Cosmetics Act, 1940 and the Drugs & Cosmetics Rules, 1945. The Act lays down legal requirements for import, manufacture, sale, distribution, standards of quality, and enforcement powers. The Act distinguishes between “new drugs” (defined under Rule 122E as drugs not approved in India or approved but marketed for less than four years) and existing drugs, with new drugs facing more stringent pre-market scrutiny. Section 26A empowers the Central Government to prohibit manufacture, sale, or distribution of drugs in the public interest, while Section 27 outlines penalties for non-compliance, including imprisonment and fines.

The Central Drugs Standard Control Organization (CDSCO) is India’s national regulator for drugs, medical devices, and cosmetics. At the helm of CDSCO is the Drugs Controller General of India (DCGI), who serves as the licensing authority for specified categories including biologicals, vaccines, and new drugs. CDSCO’s mandate extends to post-market surveillance through the Pharmacovigilance Programme of India (PvPI) and the Materiovigilance Programme of India (MvPI). Manufacturing licenses for most drugs are granted by State Drugs Control Administrations, creating a dual regulatory system where CDSCO handles central approvals while states license the majority of pharmaceutical manufacturing. Understanding this federal structure is a core competency for any pharmaceutical law firm in India advising clients on licensing strategy.

Manufacturing & GMP (Revised Schedule M, 2023)

Schedule M (under the 1945 Rules) prescribes GMP and requirements of premises, plant, and equipment for pharmaceutical products. In December 2023, the Ministry of Health & Family Welfare notified a significantly revised Schedule M under the Drugs (Amendment) Rules, 2023, aligning Indian GMP with WHO and ICH Q10 standards. The revision was driven by international scrutiny arising from incidents involving substandard exports and the need to shift from a checklist-based compliance model to a systems-based quality framework.

Key Elements of Revised Schedule M

  • Pharmaceutical Quality System (PQS): Manufacturers must implement a formal quality system encompassing all aspects of manufacturing, quality assurance, deviation handling, and continuous improvement.

  • Quality Risk Management (QRM): Risk-based decision-making is mandated across processes, deviations, change control, and critical system design.

  • Product Quality Review (PQR): Periodic comprehensive review of product performance and quality data, including complaints, deviations, CAPA, and validation outcomes.

  • Qualification & Validation: Full lifecycle qualification of utilities, equipment (IQ/OQ/PQ), and validation of critical processes is obligatory.

  • Computerised System Controls and Data Integrity: All GMP-related electronic systems must be validated; adherence to ALCOA+ principles is strictly enforced.

  • Environmental and Facility Controls: Cleanroom classifications, advanced HVAC/HEPA systems, and real-time environmental monitoring are required.

  • Documentation and Record-Keeping: Detailed and traceable documentation in line with ALCOA+ principles is mandatory.

Contract Manufacturing under Schedule M

The revised Schedule M explicitly governs contract manufacturing. The Contract Giver holds ultimate responsibility for assessing the CMO’s competence, establishing a formal technical agreement, granting audit rights, controlling subcontracting, ensuring record availability, and approving all change control actions. No changes to process, equipment, test methods, or specifications may be made without the contract giver’s approval. This structured integration ensures traceability, quality control, and accountability across the entire pharmaceutical supply chain.

Compliance Timelines

Large manufacturers (turnover exceeding Rs. 250 crores) were required to comply by June 28, 2024. SMEs with turnover of Rs. 250 crores or less were granted an extended deadline until December 31, 2025, for those who submitted an upgradation plan in Form A by May 2025. Regulatory authorities have emphasized this is the final extension. A qualified pharmaceutical company legal advisory India team can assist manufacturers in structuring their compliance roadmap and managing CDSCO interactions during this transition.

New Drugs, Clinical Trials & Ethics Oversight (NDCTR, 2019)

The New Drugs and Clinical Trials Rules (NDCTR), 2019 replaced legacy provisions with a time-bound, predictable regime covering approvals of new drugs and investigational drugs, conduct of clinical trials and BA/BE studies, import/manufacture permissions, compensation for injuries, and pathways for orphan and innovative drugs. Ethics Committees (ECs) must be constituted and registered with CDSCO via SUGAM (Form CT 01). Composition requirements include a minimum of 7 members, representation across medical and non-medical disciplines, at least one lay person, one woman member, a legal expert, and independent members; validity is typically 5 years with renewal requirements.

For Fixed Dose Combinations (FDCs), the requirements under NDCTR, 2019 govern all scenarios — from combinations containing unapproved new drugs to those already marketed in India. Rule 80 of the NDCTR sets out the application requirements under Form CT-21 for new drugs already approved in the country. Exemption from local clinical trials may be granted by CDSCO where the new drug is approved and marketed in specified countries and no major unexpected serious adverse events have been reported. Top tech law firms in Delhi with pharma regulatory capabilities advise clients extensively on FDC approval strategy and clinical trial exemption applications.

Import & Export Pathways

The import of drugs into India is strictly regulated under the Drugs and Cosmetics Act, with CDSCO coordinating import clearance through its 16 port offices via a specialised online clearance system. Obtaining a Registration Certificate in Form 41 is a mandatory prerequisite for foreign site registration, followed by specific import licenses such as Form 10 for commercial finished formulations. Form 45 permits the import of finished formulations of new drugs; Form 45A covers raw materials or new bulk drug substances. Every consignment of imported drugs must be accompanied by a test or analysis report, and labelling must adhere to Rule 96 standards.

The export landscape was modernised in May 2025 with the centralisation of the Export No Objection Certificate (NOC) issuance process to CDSCO Zonal offices. A two-step procedure was introduced: online registration through an Integrated Registration Form (IRF) on SUGAM, valid for one year, with CDSCO mandated to decide within 7 working days; followed by consignment release at the port. For unapproved formulations, manufacturers can now provide approval status from a Stringent Regulatory Authority (SRA) — such as the US FDA, EU EMA, or equivalent bodies — as an alternative to importing country NRA approval. Best tech law firms in delhi regularly advise exporters on navigating these updated NOC requirements and SRA recognition provisions.

Price Control & Market Access (NPPA & DPCO, 2013)

Pharmaceutical pricing in India is governed by the Drug Price Control Order (DPCO), 2013, promulgated under the Essential Commodities Act, 1955. The National Pharmaceutical Pricing Authority (NPPA) enforces the DPCO, fixing and revising prices for scheduled formulations, monitoring prices for non-scheduled drugs, and recovering overcharged amounts. The DPCO, 2013 expanded price control from 74 bulk drugs to over 348 essential medicines covering approximately 30% of the Indian pharmaceutical market by value.

For scheduled formulations, NPPA fixes ceiling prices using a market-based method — the simple average of Price to Retailer (PTR) for all brands and generics with at least 1% market share. Manufacturers must display MRP (inclusive of all taxes) on labels and issue revised price lists to dealers; overcharging is prosecutable under DPCO provisions. A significant compliance event occurred in September 2025 following the 56th GST Council meeting, which reduced GST on most medicines from 12% to 5%. The NPPA issued a directive requiring all manufacturers to revise MRPs effective September 22, 2025, with failure to submit revised Form V to the IPDMS portal by October 6, 2025 deemed a violation liable for criminal prosecution under the ECA. Pharma dispute resolution lawyers india have been actively engaged by manufacturers challenging NPPA computations and managing GST-related overcharging proceedings.

State–Centre Coordination & Digital Transition

Under the Drugs and Cosmetics Act, 1940, regulatory power is divided between CDSCO (responsible for approval of new drugs, clinical trials, national standards, and import quality control) and State Drug Controllers (SDCs) (responsible for manufacturing licenses, sale and distribution, and GMP inspections). Certain specialised categories — including blood products, I.V. fluids, vaccines, and sera — are subject to joint licensing, with the State Licensing Authority granting the license only after DCGI approval.

The SUGAM portal is the centrepiece of CDSCO’s e-governance strategy. By 2025, approximately 97% of CDSCO operations had been digitised, leading to a 25% increase in operational efficiency. The Online National Drugs Licensing System (ONDLS) is designed to standardise state-level licensing; as of 2025, 16 States and Union Territories have fully boarded onto the portal. In October 2025, CDSCO mandated that all post-approval changes for clinical trials of Cell and Gene Therapeutic Products must be filed exclusively through SUGAM. India is also piloting the electronic Common Technical Document (eCTD) format, signalling alignment with ICH-developed eCTD 4.0 standards. For businesses navigating this rapidly digitising regulatory environment, working with a tech law partner or a legal service india provider that understands both the regulatory and technology dimensions of CDSCO submissions is increasingly essential to maintaining compliance and avoiding approval delays.

FAQs

India’s medicines are governed primarily by the Drugs & Cosmetics Act, 1940 and the Drugs & Cosmetics Rules, 1945. CDSCO handles central approvals including new drugs, clinical trials, and import quality control, while State Drug Controllers license the majority of pharmaceutical manufacturing. The DCGI serves as the licensing authority for biologicals, vaccines, and new drugs. This dual federal structure means manufacturers must simultaneously satisfy central and state-level obligations — an area where a pharmaceutical law firm india with cross-jurisdictional expertise adds immediate and measurable compliance value.

The December 2023 revision of Schedule M shifted India’s GMP regime from a checklist approach to a systems-based quality framework aligned with WHO GMP and ICH Q10 standards. Key obligations now include a Pharmaceutical Quality System (PQS), Quality Risk Management (QRM), Product Quality Review (PQR), full lifecycle qualification and validation, computerised system controls with ALCOA+ data integrity, and advanced environmental and facility controls. Large manufacturers were required to comply by June 28, 2024, while SMEs have until December 31, 2025. Engaging a pharmaceutical company legal advisory india team to structure the compliance roadmap and manage CDSCO interactions remains the most effective way to meet the final deadline without enforcement risk.

The New Drugs and Clinical Trials Rules (NDCTR), 2019 cover approvals of new drugs and investigational drugs, clinical trial conduct, BA/BE studies, compensation for injuries, and orphan drug pathways. Ethics Committees must be registered with CDSCO via SUGAM. For Fixed Dose Combinations (FDCs), Rule 80 sets out Form CT-21 application requirements, and exemption from local clinical trials may be granted where the new drug is already approved in specified countries with no major unexpected serious adverse events reported. Top tech law firms in delhi with pharma regulatory practices advise clients extensively on FDC approval strategy, clinical trial exemption applications, and EC registration compliance.

The export landscape was modernised in May 2025, centralising Export NOC issuance to CDSCO Zonal offices. A two-step online process was introduced — registration via an Integrated Registration Form (IRF) on SUGAM valid for one year, with a mandatory 7-working-day decision timeline, followed by consignment release at port. For unapproved formulations, SRA country approvals (US FDA, EU EMA, Canada, Japan, Australia, Switzerland) are now accepted where importing country NRA approval is unavailable. Best tech law firms in delhi regularly advise exporters on navigating these updated NOC requirements, SRA recognition provisions, and shelf-life management rules for export stock.

Accordion Contenta

The NPPA enforces the DPCO, 2013 under the Essential Commodities Act, 1955, fixing ceiling prices for scheduled formulations using the simple average PTR of all brands and generics with at least 1% market share. Overcharging is prosecutable under DPCO provisions. Following the September 2025 GST reduction on medicines from 12% to 5%, NPPA directed all manufacturers to revise MRPs by September 22, 2025, with failure to submit revised Form V to IPDMS by October 6, 2025 constituting a criminal violation under the ECA. Pharma dispute resolution lawyers india are actively engaged by manufacturers challenging NPPA price computations, managing overcharging proceedings, and navigating GST-linked compliance disputes.

By 2025, approximately 97% of CDSCO operations had been digitised through the SUGAM portal, with a 25% increase in operational efficiency. The Online National Drugs Licensing System (ONDLS) standardises state-level licensing, with 16 States and Union Territories fully onboarded. In October 2025, CDSCO mandated exclusive SUGAM filing for all post-approval changes for Cell and Gene Therapeutic Products. India is also piloting the eCTD 4.0 format, signalling alignment with ICH global submission standards. For businesses navigating this digitising environment, working with a tech law partner or a legal service india provider that understands both the regulatory and technology dimensions of CDSCO submissions is essential to maintaining compliance and avoiding approval delays.